| Identification | Back Directory | [Name]
Furo[3,4-b]pyridin-5(7H)-one, 4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]- | [CAS]
1383376-92-8 | [Synonyms]
Furo[3,4-b]pyridin-5(7H)-one, 4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]- | [Molecular Formula]
C17H12FN3O2 | [MOL File]
1383376-92-8.mol | [Molecular Weight]
309.29 |
| Chemical Properties | Back Directory | [Boiling point ]
509.7±50.0 °C(Predicted) | [density ]
1.41±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
0.89±0.20(Predicted) | [color ]
Off-white to light yellow | [InChI]
InChI=1S/C17H12FN3O2/c1-21-8-13(16(20-21)10-2-4-11(18)5-3-10)12-6-7-19-14-9-23-17(22)15(12)14/h2-8H,9H2,1H3 | [InChIKey]
XISSYJGQGSMWHO-UHFFFAOYSA-N | [SMILES]
C12COC(=O)C1=C(C1=CN(C)N=C1C1=CC=C(F)C=C1)C=CN=2 |
| Hazard Information | Back Directory | [Uses]
CK1-IN-2 (compound Nr.4) is a potent CK1 inhibitor with an IC50 values of 123, 19.8, 26.8, 74.3 nM for CK1a, CK1d, CK1e, p38a, respectively[1]. | [IC 50]
CKIα: 123 nM (IC50) | [References]
[1] Joris De Maeyer, et al. Casein kinase 1 inhibitors for use in the treatment of diseases related to dux4 expression such as muscular dystrophy and cancer. WO2020249717A1. |
|
|